Sanofi

EMA rejects Genzyme re-examination request for Kynamro

EMA rejects Genzyme re-examination request for Kynamro

Yahoo/Fly on the Wall

Sanofi’s Lemtrada MS Drug Effective in Extension Trial

Sanofi’s Lemtrada MS Drug Effective in Extension Trial

Bloomberg

Sanofi investors may sue as a class: Judge

Sanofi investors may sue as a class: Judge

Yahoo/Reuters

4 Stocks Pushing The Health Care Sector Higher

4 Stocks Pushing The Health Care Sector Higher

The Street

Longer Lasting Drugs Make For Longer Lasting Profits

Longer Lasting Drugs Make For Longer Lasting Profits

Seeking Alpha

DOJ Investigating Sanofi Over Plavix Disclosure

DOJ Investigating Sanofi Over Plavix Disclosure

Motley Fool

Merck's Big Vytorin Study Could Pose A Challenge For Amgen, Sanofi, And Regeneron, Too

Merck's Big Vytorin Study Could Pose A Challenge For Amgen, Sanofi, And Regeneron, Too

Forbes

Pharmaceutical Winners And Losers In Early 2013

Pharmaceutical Winners And Losers In Early 2013

Motley Fool

Aspen Pharmacare Offers Very Expensive Developing World Growth

Aspen Pharmacare Offers Very Expensive Developing World Growth

Seeking Alpha

Tackling Cancer: Prostate Cancer's Biggest Current and Upcoming Players

Tackling Cancer: Prostate Cancer's Biggest Current and Upcoming Players

Motley Fool